Journal club
Can vitamin D₃ supplementation reduce the time to severe asthma exacerbations in children with asthma?

Commentary on:
Forno E, et al. Effect of Vitamin D₃ supplementation on severe asthma exacerbations in children with asthma and low vitamin D levels: the VDKA randomized clinical trial. JAMA 2020; 324: 752–760.

Context
There is considerable evidence that the prevalence of asthma is increasing in industrialised countries, particularly in children and young adults [1]. Exacerbations of asthma constitute the main burden of the disease for children and their families. The majority of asthma exacerbations are triggered by respiratory viruses, most commonly rhinoviruses (RVs) [2, 3]. Host immune responses to respiratory viruses are important in asthma exacerbations. Mechanistic studies have identified immunomodulatory and anti-inflammatory roles for vitamin D [4, 5]. Figure 1 describes the actions of vitamin D on B-cells, T-cells and activated mast cells in the context of an allergen/virus-induced exacerbation of asthma. Vitamin D has also been shown to induce regulatory T-cell differentiation and interleukin (IL)-10 secretion that helps attenuate the airway smooth muscle cell hypertrophy which underlies severe asthma pathophysiology [6]. Particularly for RV, vitamin D has been shown to downregulate RV replication through induction of interferons (IFNs) and IFN-stimulated pathways [7].

Although the protective levels of vitamin D for bone health have been well described, we do not know what levels of vitamin D are needed for optimal immune responses to respiratory viral infections [8]. Vitamin D deficiency is defined as measurable levels of 25-hydroxyvitamin D below 20 ng·mL⁻¹ and vitamin D insufficiency is defined as measurable levels of 25-hydroxyvitamin D below 30 ng·mL⁻¹ [9], but these are based solely on bone markers.

There is evidence from observational cohort studies linking low 25-hydroxyvitamin D levels with asthma incidence in children [10, 11]. A systematic review of the literature on studies examining the impact of vitamin D supplementation in children with early diagnosed asthma failed to show clear positive impact [12]. Also, there is unclear evidence around the link between severity of asthma and low 25-hydroxyvitamin D levels [10]. Importantly, prior to the Vitamin D Kids Asthma (VDKA) trial [13], other studies including either preschool or school-age children had not focused only on children with low 25-hydroxyvitamin D levels or on those who are at high risk for severe asthma exacerbations (assessed by poor asthma control) [11, 14]. A recently published randomised controlled trial including younger children with vitamin D deficiency showed no positive impact of vitamin D₃ supplementation on incidence of asthma exacerbations and on asthma control [15]. It is important to understand the effect of age as a cofounder in these trial results. Preschool wheeze is
not asthma and all preschool children with wheeze do not have similar responses to treatments [16]. Table 1 summarises the main characteristics of randomised controlled trials in preschool and school-age children with asthma.

In view of the lack of conclusive evidence, a research study assessing possible protective effects of vitamin D3 supplementation in children with low 25-hydroxyvitamin D levels and asthma was missing.

### Methods

The VDKA study was a randomised, double-blind, placebo controlled clinical trial [13]. The primary outcome was the time to severe asthma exacerbation post vitamin D3 supplementation. The secondary outcomes were the time to viral-induced severe asthma exacerbation, the number of patients who were able to reduce the use of their preventer medication by half, and the cumulative dose of inhaled steroids required over the study period.

Recruitment took place in seven US healthcare centres. Children at high-risk for asthma exacerbation with vitamin D deficiency and/or viral infection were eligible. The study population included school-age children with asthma, preschool children with recurrent wheeze, and preschool and school-age children with asthma.

### Table 1: Randomised controlled trials of vitamin D3 supplementation in preschool and school-age children with asthma

| Study          | Study type                                      | Study population                          | Baseline 25(OH)D, nmol·L⁻¹ | Oral dose of vitamin D3 (intervention arm) | Outcome                                                                 |
|----------------|------------------------------------------------|--------------------------------------------|----------------------------|--------------------------------------------|-------------------------------------------------------------------------|
| Urashima et al. [17] | Randomised controlled trial                   | School-age children with asthma           | 9.5 (2.1; 6.0–15.0)        | 1200 IU·day⁻¹                             | Significant preventive effect against influenza A LRTIs                  |
| Majak et al. [18]       | Randomised controlled trial with a cohort design | School-age children with asthma           | 10.9 (3.3; 6.0–17.0)       | 500 IU·day⁻¹                              | Reduced the number of asthma exacerbations triggered by acute respiratory tract infection during 6 months of follow-up |
| Tachimoto et al. [19]    | Randomised controlled trial with a cohort design | School-age children with asthma           | 9.9 (2.3; 6.0–15.0)        | 800 IU·day⁻¹                              | Improved ACT at 6 months of follow-up                                   |
| Jensen et al. [20]       | Randomised controlled trial with a cohort design | Preschool children with recurrent wheeze | 2.9 (1.1; 1.6–5.5)         | 100,000 IU bolus plus 400 IU·day⁻¹        | No effect on use of oral corticosteroids during 6 months of follow-up   |
| Kerley et al. [21]       | Randomised controlled trial with a cohort design | School-age children with asthma           | 8.6 (2.8; 5.0–15.0)        | 2000 IU·day⁻¹                             | No significant difference in asthma control during 4 months of follow-up |
| Jat et al. [15]          | Randomised controlled trial with a cohort design | Preschool and school-age children with asthma | 8.1 (2.3; 4.0–12.0)        | 1000 IU·day⁻¹                             | No significant difference in asthma control and in the number of asthma exacerbations during 9 months of follow-up |

Data are presented as median (minimum; interquartile range), unless stated otherwise. 25(OH)D: 25-hydroxyvitamin D; LRTI: lower respiratory tract infection; ACT: asthma control test.
insufficiency (age 6–16 years old) were recruited. Asthma diagnosis was based on a history of at least one severe asthma exacerbation that required systemic steroid treatment in the preceding year or use of any asthma medications for at least 6 months over the preceding year. A forced expiratory volume in the first second of expiration (FEV₁) ≥70% of predicted was a further entry requirement. Inclusion criteria for the serum levels of 25-hydroxyvitamin D were 10 to 30 ng·mL⁻¹ (protocol changed to 14 to 30 ng·mL⁻¹ during the study).

The participants were randomised to receive 4000 IU of daily Vitamin D₃ or placebo. Both groups received an inhaled corticosteroid (fluticasone propionate) (88 µg twice per day in children aged 6–11 years and 110 µg twice per day in children ≥12 years). Prior asthma medications were discontinued. 25-hydroxyvitamin D levels were measured at randomisation and every 16 weeks. Participants’ asthma control was assessed 24 weeks after recruitment by using the Asthma Control Test (ACT). Adherence to medications was assessed electronically and via returned pill counts.

Results

The VDKA study aimed to recruit 400 participants, however the trial recruitment was stopped early based on interim analysis due to lack of efficacy of vitamin D₃ supplementation. The study recruited 192 participants equally distributed in both groups and showed that vitamin D₃ supplementation did not impact on the time to a severe asthma exacerbation as compared with placebo. The mean number of days until a severe exacerbation was 240 days in the vitamin D₃ group and 253 days in the placebo group with a mean difference of −13.1 days (p=0.63). The study also found no significant difference for any of the secondary outcomes.

Children who received vitamin D₃ supplementation were significantly more likely to achieve a 25-hydroxyvitamin D level higher than 30 ng·mL⁻¹ compared with the placebo group (87.2% versus 30.1%, respectively, at 48 weeks; p-value <0.001). They reached mean 25-hydroxyvitamin D levels of 49.4 ng·mL⁻¹ (95% CI 44.9–53.9 ng·mL⁻¹) at 48 weeks compared with 24.6 ng·mL⁻¹ (95% CI 22.9–26.3 ng·mL⁻¹) in the placebo group.

The authors demonstrated statistically that both groups were similar in terms of baseline characteristics including age, ethnicity, parental education, household smoking, season of enrolment, weight, and lung function parameters.

Adverse events were similar in both groups, with hospitalisations for asthma exacerbations accounting for the majority. There were no cases of hypercalcaemia or vitamin D toxicity in either group.

Commentary

It is still unclear whether vitamin D₃ supplementation in children with vitamin D deficiency and asthma could impact positively on the incidence of asthma exacerbations. A Cochrane meta-analysis of the literature, only including double-blind, randomised trials in both adults and children with asthma, showed that vitamin D₃ supplementation could decrease the incidence of severe asthma exacerbations from 6% to around 3%, but did not have a positive impact on asthma control [22]. Interestingly, the recruitment in the VDKA trial was paused early in view of lack of efficacy of vitamin D₃ supplementation, assessed by failure to decrease incidence of severe asthma exacerbations by 16% (a high number considering previous trials [22]).

This resulted in 180 participants (92 patients in the treatment group and 88 patients in the placebo group) completing the trial with a median duration of follow-up of 332 days. Only 63 out of 180 participants (35% of the recruited patients) had serum 25-hydroxyvitamin D levels below 20 ng·mL⁻¹. Therefore, the impact of vitamin D₃ supplementation in asthmatic children with vitamin D deficiency was not assessed because of lack of statistical power. Hence the outcomes are only relevant to children with asthma and vitamin D insufficiency.

The daily dose of 4000 IU per day for vitamin D₃ supplementation is higher than the dose that has been used in other clinical trials [15]. This high dose for vitamin D₃ supplementation resulted in an increase of 25-hydroxyvitamin D levels in children with asthma from 22.5 ng·mL⁻¹ to 57.2 ng·mL⁻¹ at 16 weeks post supplementation.

Also, a total of 36 participants (37.5%) in the vitamin D₃ supplementation group and 33 participants (34.4%) in the placebo group had at least one severe asthma exacerbation during the trial. Although the authors commented that this asthma exacerbation incidence is lower than expected, US emergency department activity data have reported lower numbers of asthma exacerbations within a year in children with asthma [23]. Furthermore, this study enrolled participants with moderate asthma control, as defined by good lung capacity (FEV₁, more than 70% of predicted), and a mean baseline ACT score >19 [13].

The proportion of participants whose inhaled steroid dose could be reduced during the trial was not significantly different between the vitamin D₃ supplementation group (28 participants) and the placebo group (29 participants). Also, there was no impact of vitamin D₃ supplementation on the cumulative use of inhaled steroids during the trial. This is contrasting to evidence from the Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma (VIDA) trial, where vitamin D₃ supplementation had a significant effect on reducing the overall use of inhaled steroids [24]. The VIDA trial used an extra initial dose of oral vitamin D₃.
supplementation (100000 IU once); however, the effect on vitamin D levels following supplementation did not differ between the VKDA and the VIDA trials and could not explain the differences in the impact on use of preventive steroids.

What is clear is that vitamin D deficiency in children needs to be treated irrespective of asthma benefits. In intervention studies, patients with vitamin D deficiency or insufficiency who receive placebo need to be carefully monitored for any vitamin D deficiency-related symptoms. The VKDIA trial showed that vitamin D3 supplementation in children with asthma and 25-hydroxyvitamin D levels less than 30 ng·mL⁻¹ did not impact positively on asthma exacerbations nor improve asthma control. It is of note that these conclusions cannot be applied in children younger than 5 years old, who are more likely to have non-eosinophilic asthma phenotypes. Also, the results cannot inform decisions around the use of vitamin D₃ in patients with vitamin D deficiency.

It is therefore important that clinical trials including younger children with vitamin D deficiency will be designed so that outcomes can inform clinical practice. It is also important that these clinical trials include ethnic groups who are at higher risk for vitamin D deficiency. Clinicians need to remember that mechanistic studies showed an effect on vitamin D treatment upon respiratory viral infection. A possible study design with an increase in the dose of oral vitamin D₃ supplementation with the first symptoms of a virus-induced asthma exacerbation, might better translate the laboratory findings into clinical practice.

Implications for clinical practice

Currently, children diagnosed with asthma do not routinely undergo vitamin D testing. They might already be on oral vitamin D₃ supplementation if diagnosed with insufficiency or deficiency. The VKDIA trial showed that vitamin D₃ supplementation already be on oral vitamin D₃ supplementation (100000 IU once); however, the effect on vitamin D levels following supplementation did not differ between the VKDA and the VIDA trials and could not explain the differences in the impact on use of preventive steroids.

What is clear is that vitamin D deficiency in children needs to be treated irrespective of asthma benefits. In intervention studies, patients with vitamin D deficiency or insufficiency who receive placebo need to be carefully monitored for any vitamin D deficiency-related symptoms. The VKDIA trial showed that vitamin D₃ supplementation in children with asthma and 25-hydroxyvitamin D levels less than 30 ng·mL⁻¹ did not impact positively on asthma exacerbations nor improve asthma control. It is of note that these conclusions cannot be applied in children younger than 5 years old, who are more likely to have non-eosinophilic asthma phenotypes. Also, the results cannot inform decisions around the use of vitamin D₃ in patients with vitamin D deficiency.

It is therefore important that clinical trials including younger children with vitamin D deficiency will be designed so that outcomes can inform clinical practice. It is also important that these clinical trials include ethnic groups who are at higher risk for vitamin D deficiency. Clinicians need to remember that mechanistic studies showed an effect on vitamin D treatment upon respiratory viral infection. A possible study design with an increase in the dose of oral vitamin D₃ supplementation with the first symptoms of a virus-induced asthma exacerbation, might better translate the laboratory findings into clinical practice.

Implications for clinical practice

Currently, children diagnosed with asthma do not routinely undergo vitamin D testing. They might already be on oral vitamin D₃ supplementation if diagnosed with insufficiency or deficiency. The VKDIA trial showed that vitamin D₃ supplementation

### References

1. Burr ML, Butland BK, King S, et al. Changes in asthma prevalence: two surveys 15 years apart. Arch Dis Child 1989; 64: 1452–1456.

2. Johnston SL, A, and C Rhinoviruses: New Knowledge from an Impressive Consortium. A step forward for rhinovirus vaccine efforts or a step back? Am J Respir Crit Care Med 2021; 203: 786–788.

3. Lee SW, Yon DK, James CC, et al. Short-term effects of multiple outdoor environmental factors on risk of asthma exacerbations: Age-stratified time-series analysis. J Allergy Clin Immunol 2019; 144: 1542–1550.

4. Bleakley AS, Licciardi PV, Binks MJ. Vitamin D modulation of the innate immune response to paediatric respiratory pathogens associated with acute lower respiratory infections. Nutrients 2021; 13: 276.

5. Zhao R, Zhang W, Ma C, et al. Immunomodulatory function of vitamin D and its role in autoimmune thyroid disease. Front Immunol 2021; 12: 574967.

6. Gupta A, Spiouhes A, Richards D, et al. Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma. Am J Respir Crit Care Med 2011; 184: 1342–1349.

7. Telcian AG, Zdrenghea MT, Edwards MR, et al. Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro. Antiviral Res 2017; 137: 93–101.

8. Zdrenghea MT, Makrinioti H, Bagacian C, et al. Vitamin D modulation of innate immune responses to respiratory viral infections. Rev Med Virol 2017; 27: e1909.

9. Amrein K, Scherkl M, Hoffmann M, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr 2020; 74: 1498–1513.

10. Brehm JM, Acosta-Pérez E, Klei L, et al. Vitamin D insufficiency and severe asthma exacerbations in Puerto Rican children. Am J Respir Crit Care Med 2012; 186: 140–146.

11. Searing DA, Zhang Y, Murphy JR, et al. Decreased serum vitamin D levels in children with asthma are associated with increased corticosteroid use. J Allergy Clin Immunol 2010; 125: 995–1000.

12. Stefanidis C, Martinez AR, Nwokoro C, et al. Vitamin D for secondary prevention of acute wheeze attacks in preschool and school-age children. Thorax 2019; 74: 977–985.

13. Forno E, Bacharier LB, Phipatanakul W, et al. Effect of vitamin D3 supplementation on severe asthma exacerbations in children with asthma and low vitamin D levels: the VDKA randomized clinical trial. JAMA 2020; 324: 752–760.

14. Camargo CA, Jr, Toop L, Slyter J, et al. Effect of monthly vitamin D supplementation on preventing exacerbations of asthma or chronic obstructive pulmonary disease in older adults: post hoc analysis of a randomized controlled trial. Nutrients 2021; 13: 521.

15. Jat KR, Goel N, Gupta N, et al. Efficacy of vitamin D supplementation in asthmatic children with vitamin D deficiency: a randomized controlled trial (ESDAC trial). Pediatr Allergy Immunol 2021; 32: 479–488.

16. Bush A, Grigg J, Saglani S. Managing wheeze in preschool children. BMJ 2014; 348: g15.
Vitamin D₃ supplementation and severe asthma exacerbations in children

17. Urashima M, Segawa T, Okazaki M, et al. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. *Am J Clin Nutr* 2010; 91: 1255–1260.

18. Majak P, Olszowiec-Chlebna M, Smejda K, et al. Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection. *J Allergy Clin Immunol* 2011; 127: 1294–1296.

19. Tachimoto H, Mezawa H, Segawa T, et al. Improved control of childhood asthma with low-dose, short-term vitamin D supplementation: a randomized, double-blind, placebo-controlled trial. *Allergy* 2016; 71: 1001–1009.

20. Jensen ME, Mailhot G, Alos N, et al. Vitamin D intervention in preschoolers with viral-induced asthma (DIVA): a pilot randomised controlled trial. *Trials* 2016; 17: 353.

21. Kerley CP, Hutchinson K, Cormican L, et al. Vitamin D₃ for uncontrolled childhood asthma: a pilot study. *Pediatr Allergy Immunol* 2016; 27: 404–412.

22. Martineau AR, Cates CJ, Urashima M, et al. Vitamin D for the management of asthma. *Cochrane Database Syst Rev* 2016; 9: CD011511.

23. Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, health care use, and mortality: United States, 2005–2009. *Natl Health Stat Report* 2011; 32: 1–14.

24. Castro M, King TS, Kunselman SJ, et al. Effect of vitamin D₃ on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. *JAMA* 2014; 311: 2083–2091.